Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1803
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Cystografin (Injection, Solution)
|
| dailymed-instance:dosage |
Preparation of the patient: Appropriate
preparation is desirable for optimal
results. A laxative the night before the
examination and a low residue diet the
day before the procedure are
recommended. Dosage: The dose for retrograde use in
cystography and voiding
cystourethrography ranges from 25 to
300 mL depending on the age of the
patient and the degree of bladder
irritability; amounts greater than 300
mL may be used if the bladder capacity
allows. Best results are obtained when
the bladder is filled with the contrast
agent. If desired, the preparation may
be diluted with sterile water or sterile
saline as indicated in the table below. Administration: After sterile
catheterization, the bladder should be
filled to capacity with Cystografin using
a suitable sterile administration set.
Care should be taken to avoid using
excessive pressure. The presence of
bladder discomfort or reflux and/or
spontaneous voiding usually indicates
that the bladder is full. Radiography: The commonly employed
radiographic techniques should be
used. A scout film is recommended
before the contrast agent is
administered.
|
| dailymed-instance:descripti... |
Cystografin is a radiopaque contrast
agent supplied as a sterile, aqueous
solution. Each mL provides 300 mg
diatrizoate meglumine with 0.4 mg
edetate disodium as a sequestering
agent. Each mL of solution also
contains approximately 141 mg
organically bound iodine. At the time of
manufacture, the air in the container is
replaced by nitrogen. The preparation
should be protected from strong light.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
This preparation is contraindicated in
patients with a hypersensitivity to salts
of diatrizoic acid.
|
| dailymed-instance:supply |
Cystografin (Diatrizoate Meglumine Injection USP 30%) is available in 200 mL and 400 mL bottles containing 100 mL and 300 mL of Cystografin respectively with sufficient capacity for dilution up to 167 mL and 350 mL respectively.<br/>Storage: Store at 20-25��C (68-77��F) [See USP].Protect from light.<br/>Also Available: Cystografin Dilute (Diatrizoate
Meglumine Injection USP 18%) is also
available, as a 300 mL fill in a 400 mL
bottle.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
Safe and effective use of this
preparation depends upon proper
dosage, correct technique, adequate
precautions, and readiness for
emergencies. Retrograde cystourethrography should
be performed with caution in patients
with a known active infectious process
of the urinary tract. Sterile technique should be employed in
administration. During administration,
care should be taken to avoid excessive
pressure, rapid or acute distention of
the bladder, and trauma. Contrast agents may interfere with
some chemical determinations made on
urine specimens; therefore, urine
should be collected before
administration of the contrast medium
or two or more days afterwards.<br/>Pregnancy���Teratogenic Effects:Pregnancy Category C: Animal reproduction studies have not
been conducted with diatrizoate
meglumine injection. It is also not
known whether diatrizoate meglumine
injection can cause fetal harm when
administered to a pregnant woman or
can affect reproduction capacity.
Cystografin should be administered to a
pregnant woman only if clearly needed.
|
| dailymed-instance:genericMe... |
diatrizoate meglumine
|
| dailymed-instance:fullName |
Cystografin (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Retrograde genitourinary procedures
may cause such complications as
hematuria, perforation of the urethra or
bladder, introduction of infection into
the genitourinary tract, and oliguria or
anuria. If intravasation of this drug occurs, the
reactions which may be associated with
intravenous administration may
possibly be encountered.
Hypersensitivity or anaphylactoid
reactions may occur. Severe reactions
may be manifested by edema of the
face and glottis, respiratory distress,
convulsions or shock; such reactions
may prove fatal unless promptly
controlled by such emergency
measures asmaintenance of a clear
airway and immediate use of oxygen
and resuscitative drugs.
|
| dailymed-instance:warning |
Severe sensitivity reactions are more
likely to occur in patients with a
personal or family history of bronchial
asthma, significant allergies, or
previous reactions to contrast agents. A history of sensitivity to iodine per se
or to other contrast agents is not an
absolute contraindication to the use of
diatrizoate meglumine, but calls for
extreme caution in administration.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Cystografin
|